The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of Cellu Tissue Holdings, Inc. by Clearwate...
September 16 2010 - 3:25PM
Business Wire
Robbins Umeda LLP has commenced an investigation into possible
breaches of fiduciary duty and other violations of state law by
members of the Board of Directors ("Board") of Cellu Tissue
Holdings, Inc. ("Cellu Tissue" or the "Company") (NYSE: CLU) in
connection with their efforts to sell Cellu Tissue to Clearwater
Paper Corporation ("Clearwater Paper") (NYSE: CLW). If the
transaction is completed, Cellu Tissue shareholders will receive
$12.00 in cash for each share of Cellu Tissue common stock they
hold. The transaction is expected to be completed in the fourth
quarter of 2010.
Robbins Umeda LLP's investigation concerns whether the Cellu
Tissue's Board undertook a fair process to obtain fair
consideration for all shareholders of Cellu Tissue. Specifically,
our investigation concerns whether the Company's Board breached
their fiduciary duties to Cellu Tissue shareholders by failing to
adequately shop the Company before entering into the transaction
with Clearwater Paper. Of note, at least one analyst set a target
price for the Company at $16.00 per share. Furthermore, the Company
had an initial public offering on January 21, 2010, at which time
the stock was offered at $13.00 per share, which is 8.33% higher
than Clearwater's bid.
If you are a shareholder of Cellu Tissue, plan to continue to
hold your shares, and would like more information about your rights
as a shareholder, please contact attorney Gregory E. Del Gaizo at
800-350-6003 or by e-mail at info@robbinsumeda.com.
Robbins Umeda LLP is a California-based law firm with
significant experience representing investors in merger-related
shareholder class actions, shareholder derivative actions, and
securities fraud class actions. For more information about the
firm, please go to http://www.robbinsumeda.com.
Advertisement
Canada Life (NYSE:CLU)
Historical Stock Chart
From Jan 2025 to Feb 2025
Canada Life (NYSE:CLU)
Historical Stock Chart
From Feb 2024 to Feb 2025